Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the Cryptococcus Genus

Grants

Funding Acknowledgements

V. Arsic Arsenijevic reports research grants and consultation honoraria from Pfizer and received speaker fees from Astellas, Pfizer, and Schering-Plough. O. A. Cornely reports research grants from Actelion, Aramis Pharma, Astellas, AstraZeneca, Basilea, Bayer, Cidara, Duke University (NIH UM1AI104681), F2G, Gilead, GSK, Leeds University, MedPace, Melinta Therapeutics, Merck/MSD, Miltenyi, Pfizer, Rempex, Roche, Sanofi Pasteur, Scynexis, Seres Therapeutics, and The Medicine Company, is a consultant to Achaogen, Anacor, Amplyx, Actelion, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Matinas, Menarini Ricerche, Merck/MSD, Paratek Pharmaceuticals, Scynexis, Seres, Summit, Tetraphase, and Vical, and received lecture honoraria from Astellas, Basilea, Gilead, and Merck/MSD outside the submitted work. K. Lagrou has received research grants, travel support, and lecture honoraria from Gilead, MSD, and Pfizer. J. F. Meis received grants from Astellas, Basilea, F2G, and Merck, and he has been a consultant to Astellas, Basilea, and Merck and received speaker's fees from Merck, Gilead, and United Medical. F. de Queiroz Telles Filho received grants from Gilead, MSD, Pfizer, and TEVA as a speaker, consultant, congress chairman, and for research. P. E. Verweij received research grants from Astellas, F2G, Gilead Sciences, and Merck and received honorarium for lectures from Gilead Sciences, Bio-Rad, and Merck. All other authors have no conflicts of interest to disclose.